SEC Form 4 · accession 0001179110-16-029382
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Avery W Catlin
Officer — Sr. VP & CFO
Period of report
Sep 2, 2016
Accepted (ET)
Sep 7, 2016 · 12:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001 per share | Sep 2, 2016 | M | 10,000 | $2.80 | A | 83,586 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $2.80 | Sep 2, 2016 | M | 10,000 | D | — | Aug 5, 2021 | Common Stock | 10,000 | 25,000 | D |
Explanation of responses
- F1As of August 5, 2015, the option is fully vested.